Chronic wounds — defined as wounds failing to heal within 12 weeks — affect 2.5% of the US population, cost $50 billion annually in healthcare expenditures, and are associated with 27% of lower-extremity amputations in the US. Diabetic foot ulcers (DFUs), venous leg ulcers (VLUs), and pressure injuries represent the dominant etiologies. For wounds that fail to progress with standard moist wound care, debridement, and offloading, advanced wound therapies — biologics, skin substitutes, and adjunctive devices — offer evidence-based escalation options.
Becaplermin (PDGF-BB) and Growth Factors
Becaplermin (Regranex) — recombinant human platelet-derived growth factor BB (rh-PDGF-BB) — is FDA-approved for DFUs. The pivotal trial (Steed et al., 1995, Plastic and Reconstructive Surgery): 48.2% complete healing at 20 weeks versus 25% placebo (NNT 4.3) for Wagner grade 1–2 DFUs on adequate offloading. Mechanism: PDGF-BB stimulates fibroblast and smooth muscle cell chemotaxis and proliferation, enhancing wound granulation. Black box warning: 3× increased risk of death from malignancy with use of ≥3 tubes — limits use in patients with active malignancy and requires informed consent discussion. Current evidence suggests careful patient selection for becaplermin produces meaningful wound closure benefit for DFUs failing conservative care.
Cellular and Tissue-Based Products (CTPs)
Apligraf (Organogenesis): bilayered living skin equivalent (allogeneic keratinocytes + fibroblasts in bovine collagen matrix). RCT evidence in VLUs (Falanga 1998, JAMA Dermatology): 63% complete healing at 6 months vs. 49% compression alone. DFU RCT (Veves 2001, Diabetes Care): 56% vs. 38% healing at 12 weeks. Dermagraft (human neonatal dermal fibroblasts in polyglactin mesh): DFU RCT: 30% vs. 18% complete healing at 12 weeks. Significantly superior to standard care for DFUs failing conservative management. NPWT (negative pressure wound therapy/wound VAC): continuous or intermittent subatmospheric pressure (−75 to −125 mmHg) at wound surface — reduces edema, increases perfusion, stimulates granulation, and removes exudate. Evidence: significantly accelerates wound closure compared to standard moist wound care for DFUs, post-surgical wounds, and complex acute wounds. NPWT contraindicated in wounds with exposed vessels, organs, or untreated osteomyelitis. Hyperbaric oxygen (HBO) for DFUs: systematic review (Kranke 2012, Cochrane): HBO significantly reduces major amputation risk in DFUs at 1 year (RR 0.29) — appropriate for Wagner grade 3–4 DFUs with failed conservative care. Our wound care catalog includes comprehensive wound dressings, advanced wound care products, debridement supplies, and wound closure materials — from basic hydrocolloids and silicone foam dressings to specialty wound care products supporting all stages of chronic wound management. Our IV vascular access section supports patients receiving parenteral nutritional support during wound healing.
